Compare Amylx Pharmaceuticals Inc (AMLX) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.64B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.77. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | QDTE | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $24.19 | $36.60 |
52-Week Low | $7.82 | $26.85 |
Enterprise Value | $2.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
QDTE trades at $29.69 with a 1.19% daily gain, but technical indicators signal bearish momentum with resistance at $30. The ETF faces fundamental concerns as its high distribution yield appears funded by return of capital rather than organic earnings, potentially eroding NAV over time. Recent news highlights growing skepticism about the sustainability of its 24% yield strategy.
Outlook remains cautious due to structural yield concerns and NAV erosion risks. While weekly distributions attract income seekers, the fund's reliance on return of capital poses significant long-term value destruction risks. Investors should weigh high current income against potential principal erosion in volatile market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
